Diagnostic value of stress thallium-201/rest technetium-99m-sestamibi sequential dual isotope high-speed myocardial perfusion imaging for the detection of haemodynamically relevant coronary artery stenosis.


Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
08 2019
Historique:
received: 20 08 2017
revised: 04 01 2018
pubmed: 31 1 2018
medline: 22 9 2020
entrez: 31 1 2018
Statut: ppublish

Résumé

The aim of this study was to determine the diagnostic accuracy of stress thallium-201/rest technetium-99m-sestamibi sequential dual-isotope high-speed myocardial perfusion imaging (DI-HS-MPI) against invasively determined fractional flow reserve (FFR). Fifty-four consecutive patients prospectively underwent DI-HS-MPI before invasive coronary angiography. Perfusion was scored visually by summed stress score on a patient and coronary territory basis. Significant coronary artery disease (CAD) was defined by the presence of ≥ 90% stenosis/occlusion or fractional flow reserve ≤ 0.80 for coronary stenosis ≥ 50%. FFR was measured in 69 of 162 coronary vessels, with 1.28 ± 0.56 vessels assessed/patient. Sensitivity, specificity, and diagnostic accuracy of MPI for the detection of significant CAD were 92.8%, 69.2%, and 81.4%, on a patient basis, and 83.7%, 90.4%, and 88.8% by coronary territory. DI-HS-MPI accurately detects functionally significant CAD as defined by using FFR.

Sections du résumé

BACKGROUND
The aim of this study was to determine the diagnostic accuracy of stress thallium-201/rest technetium-99m-sestamibi sequential dual-isotope high-speed myocardial perfusion imaging (DI-HS-MPI) against invasively determined fractional flow reserve (FFR).
METHODS
Fifty-four consecutive patients prospectively underwent DI-HS-MPI before invasive coronary angiography. Perfusion was scored visually by summed stress score on a patient and coronary territory basis. Significant coronary artery disease (CAD) was defined by the presence of ≥ 90% stenosis/occlusion or fractional flow reserve ≤ 0.80 for coronary stenosis ≥ 50%.
RESULTS
FFR was measured in 69 of 162 coronary vessels, with 1.28 ± 0.56 vessels assessed/patient. Sensitivity, specificity, and diagnostic accuracy of MPI for the detection of significant CAD were 92.8%, 69.2%, and 81.4%, on a patient basis, and 83.7%, 90.4%, and 88.8% by coronary territory.
CONCLUSIONS
DI-HS-MPI accurately detects functionally significant CAD as defined by using FFR.

Identifiants

pubmed: 29380286
doi: 10.1007/s12350-018-1189-8
pii: 10.1007/s12350-018-1189-8
doi:

Substances chimiques

Radiopharmaceuticals 0
Thallium Radioisotopes 0
Technetium Tc 99m Sestamibi 971Z4W1S09
Thallium-201 H91Z8HBK1B

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1269-1279

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Circulation. 1999 Oct 5;100(14):1521-7
pubmed: 10510055
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
Am J Cardiol. 1992 Jan 15;69(3):183-7
pubmed: 1731457
Eur Heart J. 2007 Oct;28(19):2320-5
pubmed: 17656351
Circulation. 2008 Oct 14;118(16):1668-74
pubmed: 18852377
N Engl J Med. 2009 Jan 15;360(3):213-24
pubmed: 19144937
JACC Cardiovasc Imaging. 2009 Mar;2(3):273-82
pubmed: 19356571
J Am Coll Cardiol. 2010 May 4;55(18):1965-74
pubmed: 20430269
Circ Cardiovasc Imaging. 2011 Jan;4(1):51-8
pubmed: 21068188
J Am Coll Cardiol. 2011 Jan 4;57(1):70-5
pubmed: 21185504
Am J Cardiol. 1990 Dec 15;66(20):1438-44
pubmed: 2147536
Eur Heart J. 2012 Jan;33(1):67-77
pubmed: 21810860
N Engl J Med. 2012 Sep 13;367(11):991-1001
pubmed: 22924638
JACC Cardiovasc Imaging. 2013 May;6(5):600-9
pubmed: 23582358
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1542-8
pubmed: 23703458
J Nucl Cardiol. 2013 Oct;20(5):763-73
pubmed: 23737160
Circ Cardiovasc Interv. 2013 Jun;6(3):231-6
pubmed: 23756697
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Circulation. 2013 Dec 17;128(24):2557-66
pubmed: 24141255
Eur J Nucl Med Mol Imaging. 2014 May;41(5):956-62
pubmed: 24310438
J Am Coll Cardiol. 2014 Feb 4;63(4):380-406
pubmed: 24355759
Circ J. 2014;78(5):1169-75
pubmed: 24572492
Eur Heart J. 2014 Oct 21;35(40):2831-8
pubmed: 24644308
Eur J Radiol. 2014 Jun;83(6):951-956
pubmed: 24666512
J Nucl Cardiol. 2014 Aug;21(4):703-11
pubmed: 24807622
Circ J. 2014;78(11):2727-34
pubmed: 25241891
J Am Coll Cardiol. 2014 Oct 7;64(14):1464-75
pubmed: 25277618
JACC Cardiovasc Imaging. 2014 Nov;7(11):1098-105
pubmed: 25306540
Nat Rev Cardiol. 2015 Jan;12(1):48-62
pubmed: 25311229
J Nucl Cardiol. 2015 Jun;22(3):513-22
pubmed: 25381092
J Am Coll Cardiol. 2014 Nov 4;64(18):1894-904
pubmed: 25444143
Circ Cardiovasc Imaging. 2015 Jan;8(1):null
pubmed: 25596143
Clin Radiol. 2015 May;70(5):476-86
pubmed: 25623512
Eur Heart J. 2015 Jul 7;36(26):1689-96
pubmed: 25898845
J Nucl Med. 2015 Nov;56(11):1712-7
pubmed: 26338893
J Nucl Med. 2017 Jan;58(1):1-6
pubmed: 27493264
Circulation. 2017 Mar 14;135(11):1075-1092
pubmed: 28289007
JACC Cardiovasc Imaging. 2017 Jul;10(7):787-794
pubmed: 28330657
J Nucl Cardiol. 2018 Jun;25(3):1017-1022
pubmed: 29209950
Am J Cardiol. 1996 Feb 15;77(5):350-4
pubmed: 8602561

Auteurs

Gilles Barone-Rochette (G)

Department of Cardiology, University Hospital, Grenoble Alpes, France. GBarone@chu-grenoble.fr.
INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble Alpes, France. GBarone@chu-grenoble.fr.
French Alliance Clinical Trial, French Clinical Research Infrastructure Network, Paris, France. GBarone@chu-grenoble.fr.

Feras Zoreka (F)

Department of Cardiology, University Hospital, Grenoble Alpes, France.

Loïc Djaileb (L)

Department of Nuclear medicine, University Hospital, Grenoble Alpes, France.

Nicolas Piliero (N)

Department of Cardiology, University Hospital, Grenoble Alpes, France.

Alex Calizzano (A)

Department of Nuclear medicine, University Hospital, Grenoble Alpes, France.

Jean Louis Quesada (JL)

Center of Clinical Investigations, Grenoble Alpes University Hospital, Grenoble, France.

Alexis Broisat (A)

INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble Alpes, France.

Laurent Riou (L)

INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble Alpes, France.

Jacques Machecourt (J)

Department of Cardiology, University Hospital, Grenoble Alpes, France.

Daniel Fagret (D)

INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble Alpes, France.
Department of Nuclear medicine, University Hospital, Grenoble Alpes, France.

Gerald Vanzetto (G)

Department of Cardiology, University Hospital, Grenoble Alpes, France.
INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble Alpes, France.
French Alliance Clinical Trial, French Clinical Research Infrastructure Network, Paris, France.

Catherine Ghezzi (C)

INSERM U1039, Bioclinic Radiopharmaceutics Laboratory, Grenoble Alpes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH